Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon, Inc. (Nasdaq: ANNX) is a biopharmaceutical company developing complement inhibitors and targeted immunotherapies for serious neuroinflammatory and classical complement-mediated diseases. The Annexon news feed on Stock Titan aggregates company announcements, clinical updates, regulatory milestones and capital markets activity related to its C1q-focused platform.
Recent news highlights Annexon’s late-stage programs, including tanruprubart for Guillain-Barré syndrome (GBS), vonaprument for dry age-related macular degeneration with geographic atrophy (GA), and ANX1502, an oral C1s inhibitor for autoimmune conditions such as cold agglutinin disease. Investors can follow updates on the European Marketing Authorization Application for tanruprubart in GBS, plans for a Biologics License Application in the U.S., and progress of the global Phase 3 ARCHER II trial of vonaprument in GA.
News items also cover proof-of-concept work for ANX1502, financial results, public offerings of common stock and pre-funded warrants, and participation in major healthcare and investor conferences. Annexon regularly reports on its cash runway, research and development spending, and key anticipated milestones across its portfolio.
This page provides a centralized view of Annexon’s press releases and related coverage, allowing readers to track clinical data readouts, regulatory submissions, financing transactions and corporate presentations as the company advances its complement-based neuroinflammation platform.
Annexon (NASDAQ: ANNX) reported fourth-quarter and full-year 2025 results, highlighted portfolio progress, and outlined 2026 milestones. Key updates: ARCHER II topline Phase 3 data expected Q4 2026, tanruprubart MAA filed in EU with a planned U.S. BLA submission in 2026, and ANX1502 POC data anticipated in 2026.
Financials: $238.3 million cash and short-term investments at 12/31/2025 (runway into H2 2027); 2025 net loss $208.5 million; 2025 R&D expense $184.7 million.
Annexon (Nasdaq: ANNX) granted an inducement option to a new non-executive employee under its 2022 Employment Inducement Award Plan.
The board approved the award on March 12, 2026; the option to buy 20,000 shares was granted at a $5.66 exercise price on March 13, 2026, carries a ten-year term and vests over four years (25% at year one, then monthly 1/48th).
Annexon (Nasdaq: ANNX) announced that Douglas Love, president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 9:50 a.m. ET.
A live webcast will be available via the company’s Investors "Events & Presentations" page and a replay will be archived for 30 days following the presentation.
Annexon (Nasdaq: ANNX) will host an in-person and virtual key opinion leader (KOL) event in New York on Wednesday, March 18, 2026, with presentations at 2:00 PM ET and a reception at 4:00 PM ET.
Expert retina specialists will review dry age-related macular degeneration with geographic atrophy, the role of C1q, Annexon’s neuroprotective C1q inhibitor vonaprument, and the pivotal Phase 3 ARCHER II trial, with topline data expected in the second half of 2026.
Annexon (Nasdaq: ANNX) announced inducement equity awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on January 9, 2026 in accordance with Nasdaq Listing Rule 5635(c)(4). In aggregate the hires received options to purchase 155,000 shares of common stock. The options have a 10-year term, an exercise price of $6.16 per share (the closing price on January 15, 2026, the grant date), and vest over 4 years with 25% vesting at the first anniversary and the remainder vesting monthly thereafter, subject to continued service.
Annexon (NASDAQ: ANNX) outlined 2026 priorities and registrational milestones for its targeted immunotherapy platform. Key updates: MAA filed for tanruprubart in Europe with a planned U.S. BLA submission in 2026 supported by the FORWARD study; vonaprument Phase 3 ARCHER II enrollment completed (659 patients) with topline data expected in H2 2026; ANX1502 proof-of-concept readout in cold agglutinin disease expected in 2026. Company states a strong cash position funding operations into late 2027 and plans a GA Investor Day in March 2026.
Annexon (Nasdaq: ANNX) submitted a Marketing Authorization Application (MAA) to the European Medicines Agency on Jan 8, 2026 for tanruprubart to treat Guillain-Barré syndrome (GBS).
The dossier includes randomized placebo-controlled proof-of-concept and pivotal Phase 3 data showing rapid reduction of neuroinflammation after a single infusion, measurement of improved functional and disability outcomes, a large U.S. and Southeast Asian biomarker dataset, population PK across regions, and a real-world evidence comparison to IVIg/plasma exchange. Tanruprubart has European and FDA Orphan Drug designations. An FDA BLA submission using FORWARD study data is planned in 2026.
Annexon (Nasdaq: ANNX) announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST. A live webcast will be available under the Events & Presentations section on the company’s Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
Annexon (Nasdaq: ANNX) granted an inducement equity award to a new non-executive employee under its 2022 Employment Inducement Award Plan, approved December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
The award is an option to purchase 19,000 shares, with a 10-year term, an exercise price of $4.91 per share (closing price on December 15, 2025, the grant date), and a standard four-year vesting schedule: 25% vesting after one year and the remainder vesting monthly at 1/48th thereafter, subject to continued service.
Annexon (Nasdaq: ANNX) closed an underwritten public offering on Nov 14, 2025, issuing 29,423,075 shares of common stock including the full exercise of a 4,326,922-share underwriters’ option and issuing 3,750,000 pre-funded warrants.
The public offering price was $2.60 per share (pre-funded warrant price $2.599) and gross proceeds were approximately $86.25 million before fees. Goldman Sachs, TD Cowen and Wells Fargo served as joint book-running managers.